coronafacic acid: a polyketide that is coupled to coronamic acid by coronafacate ligase to form coronatine; structure given in first source; RN refers to (3aS-(3aalpha,6beta,7aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 114969 |
CHEBI ID | 80089 |
MeSH ID | M0223958 |
Synonym |
---|
coronafacic acid |
62251-98-3 |
(3as,6r,7as)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroindene-4-carboxylic acid |
1h-indene-4-carboxylic acid, 6-ethyl-2,3,3a,6,7,7a-hexahydro-1-oxo-, (3as,6r,7as)- |
1h-indene-4-carboxylic acid, 6-ethyl-2,3,3a,6,7,7a-hexahydro-1-oxo-, (3as-(3alpha,6beta,7aalpha))- |
6-ethyl-2,3,3as,6r,7,7as-hexahydro-1-oxo-1h-indene-4-carboxylic acid |
CHEBI:80089 |
AKOS026743250 |
(3as,6r,7as)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydro-1h-indene-4-carboxylic acid |
Q27149241 |
DTXSID80977827 |
(3as,6r,7as)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydro-1h-indene-4-carboxylicacid |
CS-0168710 |
rel-(3as,6r,7as)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydro-1h-indene-4-carboxylic acid |
CS-0168706 |
EN300-152203 |
rel-(3ar,6s,7ar)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydro-1h-indene-4-carboxylic acid |
66322-23-4 |
EN300-1588500 |
Excerpt | Reference | Relevance |
---|---|---|
"Coronafacic acid has been synthesized from a hydrindanone prepared by the cyclization reaction of the enone-aldehyde with samarium (II) iodide." | ( [6-endo-trig mode cyclization to a hydrindanone using samarium (II) iodide]. Sono, M, 2003) | 1.04 |
Class | Description |
---|---|
ketone | A compound in which a carbonyl group is bonded to two carbon atoms: R2C=O (neither R may be H). |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (31.82) | 18.2507 |
2000's | 6 (27.27) | 29.6817 |
2010's | 9 (40.91) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.71) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.55%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (95.45%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |